A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma

Phase 2 Active not recruiting 87 enrolled Xynomic Pharmaceuticals, Inc.

NaSingle-groupOpen-labelTreatment

Summary

An open-label, single-arm, multi-center phase 2 study to evaluate the efficacy and safety of oral histone deacetylase (HDAC)-inhibitor abexinostat, as monotherapy in patients with relapsed or refractory follicular lymphoma (FL)

Timeline

Start: 2020-04-22
Primary completion: 2025-01-29
Completion: 2025-10-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Abexinostat	Small molecule	80 mg	Oral

A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma

Summary

Timeline

Drugs

Indications